Neurology
-
Randomized Controlled Trial Multicenter Study
Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study.
To evaluate the efficacy, safety, and tolerability of oxcarbazepine (1,200 mg/day) vs placebo as prophylactic therapy for patients with migraine headaches. ⋯ Overall, oxcarbazepine was safe and well tolerated; however, oxcarbazepine did not show efficacy in the prophylactic treatment of migraine headaches.
-
Randomized Controlled Trial Multicenter Study
Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy.
To assess the efficacy and tolerability of adjunctive levetiracetam in patients with uncontrolled generalized tonic-clonic (GTC) seizures associated with idiopathic generalized epilepsies (IGE). ⋯ Adjunctive levetiracetam is an effective and well-tolerated antiepileptic drug for treating generalized tonic-clonic seizures in patients with idiopathic generalized epilepsies.
-
Randomized Controlled Trial
Phase II/III randomized trial of TCH346 in patients with ALS.
TCH346 exerts antiapoptotic effects by binding to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and blocking the apoptotic pathway in which GAPDH is involved. Apoptosis is considered to be a key pathogenic mechanism in neurodegenerative diseases including ALS. ⋯ The trial revealed no evidence of a beneficial effect of TCH346 on disease progression in patients with ALS.
-
Randomized Controlled Trial Multicenter Study
Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.
The CALM-PD trial evaluated the development of motor complications in subjects with early Parkinson disease (PD) randomized to initial treatment with either pramipexole or levodopa. A secondary finding of the trial was a higher than anticipated development or worsening of somnolence and edema and development of hallucinations. ⋯ Comorbid illnesses are important and overlooked risk factors for the development of somnolence, edema, and hallucinations. When initiating therapy with pramipexole, patients should be counseled about and monitored for somnolence and edema. Slight decrements in cognitive function and older age are associated with an increased risk of hallucinations.
-
Randomized Controlled Trial Comparative Study
Prednisolone does not reduce withdrawal headache: a randomized, double-blind study.
Medication overuse headache is a condition where abrupt drug withdrawal is considered the treatment of choice. ⋯ Prednisolone has no effect on withdrawal headache in unselected patients with chronic daily headache and medication overuse.